Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
Seamless Therapeutics inks research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss: Dresden, Germany Friday, January 30, 2026, 15 ...
In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results